MX2023015379A - Metodos y dispositivos terapeuticos. - Google Patents

Metodos y dispositivos terapeuticos.

Info

Publication number
MX2023015379A
MX2023015379A MX2023015379A MX2023015379A MX2023015379A MX 2023015379 A MX2023015379 A MX 2023015379A MX 2023015379 A MX2023015379 A MX 2023015379A MX 2023015379 A MX2023015379 A MX 2023015379A MX 2023015379 A MX2023015379 A MX 2023015379A
Authority
MX
Mexico
Prior art keywords
site
analyte
sensor
delivery
determination
Prior art date
Application number
MX2023015379A
Other languages
English (en)
Spanish (es)
Inventor
Sven Magnus Carlsen
Sverre Christian Christiansen
Anders Lyngvi Fougner
Øyvind Stavdahl
Reinold Ellingsen
Dag Roar Hjelme
Original Assignee
Norwegian Univ Sci & Tech Ntnu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwegian Univ Sci & Tech Ntnu filed Critical Norwegian Univ Sci & Tech Ntnu
Publication of MX2023015379A publication Critical patent/MX2023015379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6848—Needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
MX2023015379A 2021-06-24 2022-06-23 Metodos y dispositivos terapeuticos. MX2023015379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2109087.3A GB202109087D0 (en) 2021-06-24 2021-06-24 Therapeutic methods and devices
PCT/EP2022/067148 WO2022268941A1 (en) 2021-06-24 2022-06-23 Therapeutic methods and devices

Publications (1)

Publication Number Publication Date
MX2023015379A true MX2023015379A (es) 2024-03-26

Family

ID=77179556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015379A MX2023015379A (es) 2021-06-24 2022-06-23 Metodos y dispositivos terapeuticos.

Country Status (7)

Country Link
US (1) US20250276127A1 (enExample)
EP (1) EP4358993A1 (enExample)
JP (1) JP2024528457A (enExample)
CN (1) CN117881417A (enExample)
GB (1) GB202109087D0 (enExample)
MX (1) MX2023015379A (enExample)
WO (1) WO2022268941A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL146496A0 (en) 2001-11-14 2002-07-25 Lycored Natural Prod Ind Ltd Carotenoid composition and method for protecting skin
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MXPA06014970A (es) * 2004-06-29 2007-03-07 Diobex Inc Composiciones y metodos para la prevencion y el control de la hipoglucemia inducida por la insulina.
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
RO123581B1 (ro) * 2009-01-29 2014-02-28 D.M. Oana Toană Metodă de monitorizare a glicemiei şi aparat de injectat insulină pacienţilor cu diabet zaharat
RU2014107515A (ru) 2011-09-19 2015-10-27 Фп Марангони Инк. Трехфазная система сепарации для буровых растворов и бурового шлама

Also Published As

Publication number Publication date
JP2024528457A (ja) 2024-07-30
US20250276127A1 (en) 2025-09-04
CN117881417A (zh) 2024-04-12
WO2022268941A1 (en) 2022-12-29
EP4358993A1 (en) 2024-05-01
GB202109087D0 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
EP2585133B1 (en) System for closed-loop control of glucose to a treatment range
AU2015274894B2 (en) Insulin delivery systems and methods
EP1848323B1 (en) Bolus estimator for semi-closed loop infusion system
CN104622480B (zh) 单针集成型人工胰腺
US8814822B2 (en) Reciprocating delivery of fluids to the body with analyte concentration monitoring
AU2011222944B2 (en) System and method for administering medicaments on the basis of urine values
CN105169525B (zh) 用于闭环胰岛素输注系统的防护技术
Rosenstock et al. Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM)
MacIsaac et al. The influence of a blood conserving device on anaemia in intensive care patients
WO2009109351A3 (de) Vorrichtung und verfahren zur überwachung eines zugangs zu einem patienten, insbesondere eines gefässzugangs bei einer extrakorporalen blutbehandlung
O'Neal et al. Feasibility of adjacent insulin infusion and continuous glucose monitoring via the Medtronic Combo-Set
Lamont et al. Effects of 2 different infusion rates of medetomidine on sedation score, cardiopulmonary parameters, and serum levels of medetomidine in healthy dogs
Schultz et al. Tight glycaemic control: a survey of intensive care practice in the Netherlands
RU2368312C2 (ru) Способ мониторинга инсулиновой терапии диабета
Giguère et al. Comparison of the effects of caffeine and doxapram on respiratory and cardiovascular function in foals with induced respiratory acidosis
RU2015145450A (ru) Способы дистанционного контроля самостоятельного введения ваноксерина для прекращения острых эпизодов аритмии сердца у млекопитающих
Horwitz et al. New technologies for glucose monitoring and insulin administration
CN203619988U (zh) 闭环药物释放系统
WO2021037650A1 (en) Skin-mountable combined drug delivery port device
CN109414228B (zh) 用于检测用户体液中的至少一种分析物的传感器设备
RU2189235C2 (ru) Способ внутривенной инфузии гипохлорита натрия
Schmidt et al. Glucose sensor excludes hypoglycaemia as cause of death
RU2337368C1 (ru) Способ коррекции нарушений перекисного окисления липидов и антиоксидантной активности при стресс-реакции после операций на щитовидной железе
Ha et al. Effects Of Progressive Combined Exercise Program On Irisin, C-peptide And Homa Index In Obese Elderly Women With Type 2 Diabetes: 505 Board# 321 May 27 10: 30 AM-12: 00 PM
KR20190021959A (ko) 냄새를 이용한 혈당감지방식의 인슐린 투여시스템